Weight ManagementAlso known as: Byetta, Bydureon, Exendin-4, AC2993
Exenatide
First-in-class GLP-1 receptor agonist derived from Gila monster saliva (exendin-4). FDA-approved as Byetta (2005) and extended-release Bydureon (2012). Pioneer of the GLP-1 agonist drug class.
Half-Life
~2.4 hours (Byetta) / ~2 weeks (Bydureon ER)
Dose Range
5-10 mcg twice daily (Byetta) or 2 mg weekly (Bydureon)
Frequency
2× daily (IR) or 1× weekly (ER)
Vial Sizes
0.25 mg, 2 mg
Mechanism of Action
Synthetic exendin-4 (39-amino acid peptide) with 53% homology to human GLP-1. Resists DPP-4 degradation naturally. Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying.
Source: PMID: 15765106 (AC2993 Phase 3)
Dosing Protocol
| Typical Dose | 5-10 mcg twice daily (Byetta) or 2 mg weekly (Bydureon) |
| Frequency | 2× daily (IR) or 1× weekly (ER) |
| Half-Life | ~2.4 hours (Byetta) / ~2 weeks (Bydureon ER) |
| Common Vial Sizes | 0.25 mg, 2 mg |
Reconstitution Example
Vial
2 mg
Water
0.65 mL
Concentration
3.08 mg/mL
Per Unit (100u syringe)
30.8 mcg
Dose of 5 mcg = 0.2 units on a 100-unit insulin syringe
Dosing Quick Reference
Exenatide— Dosing Guide
Dose Range
5-10 mcg twice daily (Byetta) or 2 mg weekly (Bydureon)
Half-Life
~2.4 hours (Byetta) / ~2 weeks (Bydureon ER)
Frequency
2× daily (IR) or 1× weekly (ER)
Route
Subcutaneous
0.25 mg vial2 mg vial
💧 0.65 mL BAC water|📐 3.08 mg/mL concentration|💉 30.8 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code